I completely agree with you @Chagsy. It does seem as though they are trying to spread their wings a little too much and this will only hurt them by taking away much needed attention from their stage II studies, and particularly DEP. The only thing that would make sense to me is if they already knew the product wasn't as safe or effective as they had hoped, but like you said there is absolutely nothing in the data or media releases that would suggest that the results are anything short of at least promising. While I understand the new 'it' thing in the pharma landscape is coming up with a COVID product and selling that to every governmental health agency around the world for trillions of dollars, their DEP product has so much more potential in regards to it's clinical results and in comparison to other treatments currently out there it improves on a lot of things. If they could bring it to market it would make them quite a lot of money. Something is fishy here. Either results aren't as good as they seem or management is doing a majorly bad job at running the company. Time will tell..